NeoGenomics (NEO) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. LRCX
7. LVS
8. CSX
9. QGEN
10. KNX

Go back to NeoGenomics (NEO) Tops Q2 EPS by 1c

NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016

July 26, 2016 7:00 AM EDT

FT. MYERS, Fla., July 26, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2016.

Second Quarter 2016 Highlights:

159% increase in consolidated revenue to record $63.1 million 158% increase in clinical genetic testing volume(1) Net income of $413,000 versus net loss of $176,000 in Q2 2015 281% increase in Adjusted EBITDA(2) to $9.2 million Diluted EPS of ($0.07) per share and Adjusted Diluted EPS(2) of $0.04 per share

Consolidated... More